Compare
Vertex Pharmaceuticals Inc vs Bausch Health Companies Inc. vs Viatris Inc vs Regeneron Pharmaceuticals, Inc.
| Latest fiscal year | Vertex Pharmaceuticals Inc VRTX | Bausch Health Companies Inc. BHC | Viatris Inc VTRS | Regeneron Pharmaceuticals, Inc. REGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.00B | $10.27B | $14.30B | $14.34B |
| Revenue growth (YoY) | +8.9% | +6.7% | -3.0% | +1.0% |
| Gross margin | 86.2% (computed) | n/a | 35.1% | n/a |
| Operating margin | 34.8% | 17.7% | -18.6% | 24.9% |
| Net margin | 32.9% | 1.2% | -24.6% | 31.4% |
| Net income | $3.95B | $120.00M | -$3.51B | $4.50B |
| EPS (Diluted) | $15.32 | $0.42 | -$3.00 | $41.48 |
| Operating cash flow | $3.63B | $1.40B | $2.32B | $4.98B |
| Free cash flow | $3.19B | $1.00B | $1.94B | $4.08B |
| Cash & equivalents | $5.08B | $1.31B | $1.32B | $3.12B |
| Total assets | $25.64B | $26.37B | $37.19B | $40.56B |
| Total liabilities | $6.98B | $25.99B | $22.48B | $9.30B |
| Shareholders' equity | $18.67B | $377.00M | $14.71B | $31.26B |
| Return on year-end equity | 21.2% | 31.8% | -23.9% | 14.4% |
| Shares outstanding | 253.99M | 370.53M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Vertex Pharmaceuticals Inc | Bausch Health Companies Inc. | Viatris Inc | Regeneron Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $12.00B Ended 2025-12-31 | $10.27B Ended 2025-12-31 | $14.30B Ended 2025-12-31 | $14.34B Ended 2025-12-31 |
| 1 year earlier | $11.02B Ended 2024-12-31 | $9.62B Ended 2024-12-31 | $14.74B Ended 2024-12-31 | $14.20B Ended 2024-12-31 |
| 2 years earlier | $9.87B Ended 2023-12-31 | $8.76B Ended 2023-12-31 | $15.43B Ended 2023-12-31 | $13.12B Ended 2023-12-31 |
| 3 years earlier | $8.93B Ended 2022-12-31 | $8.12B Ended 2022-12-31 | $16.26B Ended 2022-12-31 | $12.17B Ended 2022-12-31 |
| 4 years earlier | $7.57B Ended 2021-12-31 | $8.43B Ended 2021-12-31 | $17.89B Ended 2021-12-31 | $16.07B Ended 2021-12-31 |